Literature DB >> 28775206

Clinical Molecular Imaging of Chemokine Receptor CXCR4 Expression in Atherosclerotic Plaque Using 68Ga-Pentixafor PET: Correlation with Cardiovascular Risk Factors and Calcified Plaque Burden.

Desiree Weiberg1, James T Thackeray1, Guenter Daum2, Jan M Sohns1, Saskia Kropf3, Hans-Juergen Wester4, Tobias L Ross1, Frank M Bengel1, Thorsten Derlin5.   

Abstract

The CXC-motif chemokine receptor 4 (CXCR4) represents a promising target for molecular imaging of different CXCR4-positive cell types in cardiovascular diseases such as atherosclerosis and arterial wall injury. The aim of this study was to assess the prevalence, pattern, and clinical correlates of arterial wall accumulation of 68Ga-pentixafor, a specific CXCR4 ligand for PET.
Methods: The data for 51 patients who underwent 68Ga-pentixafor PET/CT for noncardiovascular indications were retrospectively analyzed. Tracer accumulation in the vessel wall of major arteries was analyzed qualitatively and semiquantitatively by blood-pool-corrected target-to-background ratios. Tracer uptake was compared with calcified plaque burden and cardiovascular risk factors.
Results: Focal arterial uptake of 68Ga-pentixafor was seen at 1,411 sites in 51 (100%) of patients. 68Ga-pentixafor uptake was significantly associated with calcified plaque burden (P < 0.0001) and cardiovascular risk factors including age (P < 0.0001), arterial hypertension (P < 0.0001), hypercholesterolemia (P = 0.0005), history of smoking (P = 0.01), and prior cardiovascular events (P = 0.0004). Both the prevalence (P < 0.0001) and the signal intensity (P = 0.009) of 68Ga-pentixafor uptake increased as the number of risk factors increased.
Conclusion: 68Ga-pentixafor PET/CT is suitable for noninvasive, highly specific PET imaging of CXCR4 expression in the atherosclerotic arterial wall. Arterial wall 68Ga-pentixafor uptake is significantly associated with surrogate markers of atherosclerosis and is linked to the presence of cardiovascular risk factors. 68Ga-pentixafor signal is higher in patients with a high-risk profile and may hold promise for identification of vulnerable plaque.
© 2018 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  68Ga-pentixafor; CXCR4; PET/CT; atherosclerosis; plaque

Mesh:

Substances:

Year:  2017        PMID: 28775206     DOI: 10.2967/jnumed.117.196485

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  37 in total

Review 1.  Frontiers in positron emission tomography imaging of the vulnerable atherosclerotic plaque.

Authors:  Mark G MacAskill; David E Newby; Adriana A S Tavares
Journal:  Cardiovasc Res       Date:  2019-12-01       Impact factor: 10.787

Review 2.  Atherosclerosis Immunoimaging by Positron Emission Tomography.

Authors:  Carlos Pérez-Medina; Zahi A Fayad; Willem J M Mulder
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-02-06       Impact factor: 8.311

3.  Chemokine receptors: Key for molecular imaging of inflammation in atherosclerosis.

Authors:  Yongjian Liu; Pamela K Woodard
Journal:  J Nucl Cardiol       Date:  2018-03-07       Impact factor: 5.952

Review 4.  Current and novel radiopharmaceuticals for imaging cardiovascular inflammation.

Authors:  Gyu S Heo; Deborah Sultan; Yongjian Liu
Journal:  Q J Nucl Med Mol Imaging       Date:  2020-02-18       Impact factor: 2.346

Review 5.  Clinical imaging of cardiovascular inflammation.

Authors:  Claudia Calcagno; Zahi A Fayad
Journal:  Q J Nucl Med Mol Imaging       Date:  2020-02-18       Impact factor: 2.346

6.  Imaging Biological Pathways in Abdominal Aortic Aneurysms Using Positron Emission Tomography.

Authors:  Michael Bell; Richa Gandhi; Heba Shawer; Charalampos Tsoumpas; Marc A Bailey
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-03-25       Impact factor: 8.311

Review 7.  Current and Emerging Preclinical Approaches for Imaging-Based Characterization of Atherosclerosis.

Authors:  Jonathan Vigne; James Thackeray; Jeroen Essers; Marcus Makowski; Zoreh Varasteh; Adelina Curaj; Angelos Karlas; Emmanuel Canet-Soulas; Willem Mulder; Fabian Kiessling; Michael Schäfers; René Botnar; Moritz Wildgruber; Fabien Hyafil
Journal:  Mol Imaging Biol       Date:  2018-12       Impact factor: 3.488

8.  CXCL12 promotes atherosclerosis by downregulating ABCA1 expression via the CXCR4/GSK3β/β-cateninT120/TCF21 pathway.

Authors:  Jia-Hui Gao; Lin-Hao He; Xiao-Hua Yu; Zhen-Wang Zhao; Gang Wang; Jin Zou; Feng-Jiao Wen; Li Zhou; Xiang-Jun Wan; Da-Wei Zhang; Chao-Ke Tang
Journal:  J Lipid Res       Date:  2019-10-29       Impact factor: 5.922

9.  Emerging imaging targets for infiltrative cardiomyopathy: Inflammation and fibrosis.

Authors:  Frank M Bengel; Tobias L Ross
Journal:  J Nucl Cardiol       Date:  2018-07-02       Impact factor: 5.952

10.  Radionuclide Imaging of Atherothrombotic Diseases.

Authors:  Mitchel R Stacy
Journal:  Curr Cardiovasc Imaging Rep       Date:  2019-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.